Literature DB >> 7919639

Patterns of sleep disorders and sedative hypnotic use in seniors.

E Mullan1, C Katona, M Bellew.   

Abstract

Adequate sleep is required for good physical and psychological health. Sleep disturbance is common and its prevalence increases with advancing age. Physiologically, sleep in elderly adults differs from that in younger adults, both in terms of quantity and quality. Sleep disturbance in old age may be associated with many physical and psychological conditions, and less commonly can occur as a primary disturbance. It must be distinguished from the understandable but unrealistic expectations of many elderly people that they will sleep for as long and as soundly as when they were younger. The evaluation of a patient with a sleep disorder requires full medical psychiatric and social histories, mental state and physical examinations and appropriate investigations. If present, an underlying condition should be treated. Management strategies for sleep disorders include attention to sleep hygiene, behavioural treatment and hypnotics. Ideally, a hypnotic should be prescribed for a limited period and then in the smallest effective dose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919639     DOI: 10.2165/00002512-199405010-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  36 in total

Review 1.  Psychotropic drugs and injuries among the elderly: a review.

Authors:  W A Ray
Journal:  J Clin Psychopharmacol       Date:  1992-12       Impact factor: 3.153

2.  Characteristics of subjective insomnia in the elderly living at home.

Authors:  K Morgan; H Dallosso; S Ebrahim; T Arie; P H Fentem
Journal:  Age Ageing       Date:  1988-01       Impact factor: 10.668

3.  Sleep fragmentation in patients from a nursing home.

Authors:  S Ancoli-Israel; L Parker; R Sinaee; R L Fell; D F Kripke
Journal:  J Gerontol       Date:  1989-01

4.  Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy.

Authors:  P J Shiromani; J C Gillin; S J Henriksen
Journal:  Annu Rev Pharmacol Toxicol       Date:  1987       Impact factor: 13.820

Review 5.  Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; H R Ochs; R I Shader
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

6.  Does sleep disturbance predict depression in elderly people? A study in inner London.

Authors:  G Livingston; B Blizard; A Mann
Journal:  Br J Gen Pract       Date:  1993-11       Impact factor: 5.386

Review 7.  Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

8.  Effects of age on auditory awakening thresholds.

Authors:  H Zepelin; C S McDonald; G K Zammit
Journal:  J Gerontol       Date:  1984-05

9.  Sleep disturbances in survivors of the Nazi Holocaust.

Authors:  J Rosen; C F Reynolds; A L Yeager; P R Houck; L F Hurwitz
Journal:  Am J Psychiatry       Date:  1991-01       Impact factor: 18.112

Review 10.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

View more
  3 in total

1.  Cognitive behavioral therapy for institutionalized elders complaining of sleep disturbance in Alexandria, Egypt.

Authors:  Heba M El Kady; Hala K Ibrahim; Sherine G Mohamed
Journal:  Sleep Breath       Date:  2011-12-10       Impact factor: 2.816

Review 2.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

3.  Prevalence and associated factors of insomnia syndrome in the elderly residing in kahrizak nursing home, tehran, iran.

Authors:  F Mousavi; Aa Tavabi; E Iran-Pour; R Tabatabaei; B Golestan
Journal:  Iran J Public Health       Date:  2012-01-31       Impact factor: 1.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.